Pantoprazole: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (11 intermediate revisions by 8 users not shown) | |||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Upper gastrointestinal bleeding]]=== | ===[[Upper gastrointestinal bleeding]]=== | ||
*80mg x 1; then 8mg/hr | *80mg IV x 1; then 8mg/hr OR 80mg IV BID | ||
*Intermittent dosing is comparable to bolus then continuous drip<ref>Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-1762. doi:10.1001/jamainternmed.2014.4056</ref> | |||
===[[GERD]], [[Peptic ulcer disease]], [[Esophagitis]]=== | |||
*40mg IV or PO daily | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*<5yo: safety/efficacy not established | |||
*>5yo | |||
**15 kg to <40 kg: 20 mg PO qDay | |||
**40 kg or greater: 40 mg PO qDay | |||
==Special Populations== | ==Special Populations<ref>Pantoprazole: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019. </ref>== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: | ||
** Pantoprazole is present in breast milk | |||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
*** No adjustment necessary | |||
**Pediatric | **Pediatric | ||
*** Not defined | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
*** No adjustment necessary | |||
**Pediatric | **Pediatric | ||
*** Not defined | |||
==Contraindications== | ==Contraindications== | ||
| Line 25: | Line 38: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* [[Anaphylaxis]] | |||
* [[SJS/TEN]] | |||
* Renal impairment | |||
* [[Pancreatitis]] | |||
* Hepatic impairment | |||
===Common=== | ===Common=== | ||
* Headache | |||
* abdominal pain | |||
* nausea/vomiting/diarrhea | |||
* AST/ALT elevation | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1 hour | ||
*Metabolism: | *Metabolism: Hepatic - CYP450 | ||
*Excretion: | *Excretion: Urine/Feces | ||
*Mechanism of Action: | *Mechanism of Action: inhibits gastric parietal cell H+/K+ ATPase | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category: | |||
[[Category:Pharmacology]] | |||
[[Category:GI]] | |||
Latest revision as of 00:55, 21 February 2021
General
- Type: Proton-pump inhibitor
- Dosage Forms:
- Common Trade Names: Protonix, Somac, Forppi, Pantoloc, Pantozol, Pantomed, Zurcal, Zentro, Pan, Controloc, Tecta
Adult Dosing
Upper gastrointestinal bleeding
- 80mg IV x 1; then 8mg/hr OR 80mg IV BID
- Intermittent dosing is comparable to bolus then continuous drip[1]
GERD, Peptic ulcer disease, Esophagitis
- 40mg IV or PO daily
Pediatric Dosing
- <5yo: safety/efficacy not established
- >5yo
- 15 kg to <40 kg: 20 mg PO qDay
- 40 kg or greater: 40 mg PO qDay
Special Populations[2]
- Pregnancy Rating: B
- Lactation:
- Pantoprazole is present in breast milk
- Renal Dosing
- Adult
- No adjustment necessary
- Pediatric
- Not defined
- Adult
- Hepatic Dosing
- Adult
- No adjustment necessary
- Pediatric
- Not defined
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- SJS/TEN
- Renal impairment
- Pancreatitis
- Hepatic impairment
Common
- Headache
- abdominal pain
- nausea/vomiting/diarrhea
- AST/ALT elevation
Pharmacology
- Half-life: 1 hour
- Metabolism: Hepatic - CYP450
- Excretion: Urine/Feces
- Mechanism of Action: inhibits gastric parietal cell H+/K+ ATPase
See Also
References
- ↑ Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-1762. doi:10.1001/jamainternmed.2014.4056
- ↑ Pantoprazole: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.